Acne Vulgaris
📧 Sign up to get email alerts when something new happens for Acne Vulgaris.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-17Clinical Trial Update: Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne [Phase 3]
Phase 3 trial evaluating the safety and efficacy of sarecycline for acne vulgaris has completed, with results posted in May 2018. The study …
-
CLINICAL_TRIALS trial_result · 2018-05-14Clinical Trial Update: Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring [Phase 1, Phase 2]
Completed Phase 1/2 trial evaluating microneedling with topical vitamin C for treating acne scarring and acne vulgaris, reporting efficacy o…
-
CLINICAL_TRIALS research · 2018-05-14Clinical Trial Update: Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography [NA]
A completed clinical trial update describing imaging of pilosebaceous units and acne lesions using RCM, OCT confocal microscopy, and optical…
-
CLINICAL_TRIALS trial_result · 2018-05-07Clinical Trial Update: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled trial evaluating Sarecycline for acne vulgaris has completed, and the results were po…
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris [Phase 3]
Phase 3 open-label study evaluating the safety of Sarecycline tablets for acne vulgaris. Results posted from a multi-center trial.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-05-02FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc. This approval covers changes to …
-
FDA approval · 2018-05-02FDA Approved: ISOTRETINOIN — Supplemental Application (Mayne Pharma)
FDA approved Mayne Pharma's supplemental application for isotretinoin. The action indicates a labeling or formulation update under an approv…
-
FDA approval · 2018-05-02FDA Approved: ABSORICA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ABSORICA (isotretinoin) from Sun Pharmaceutical Industries, Inc. to modify or expand its lab…
-
FDA approval · 2018-05-02FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for ZENATANE (isotretinoin) submitted by BluePoint Laboratories.
-
FDA approval · 2018-05-02FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) filed by Teva Pharmaceuticals USA, Inc.
-
FDA label_change · 2018-05-02FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for AMNESTEEM (isotretinoin) filed by Mylan Pharmaceuticals Inc., resulting in a label update for th…
-
FDA approval · 2018-05-02FDA Approved: ISOTRETINOIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approves a supplemental application for isotretinoin from Amneal Pharmaceuticals NY LLC.
-
CLINICAL_TRIALS research · 2018-05-02Clinical Trial Update: Prevalence of H.Pylori in Patients With Acne Vulgaris Acne Vulgaris
The completed trial investigated the prevalence of Helicobacter pylori infection in patients with acne vulgaris.
-
CLINICAL_TRIALS trial_result · 2018-04-27Clinical Trial Update: Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects [Phase 3]
Phase 3 results for the GSK investigational compound GSK2585823 (STF115287) in acne vulgaris in Japanese subjects have been posted.
-
FDA approval · 2018-04-23FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2018-04-23FDA Approved: ISOTRETINOIN — Supplemental Application (Mayne Pharma)
FDA approves a supplemental application for isotretinoin submitted by Mayne Pharma, bringing changes to the product under its existing appro…
-
FDA label_change · 2018-04-23FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Zenatane (isotretinoin) submitted by BluePoint Laboratories. The document indicates a supplement…
-
FDA label_change · 2018-04-23FDA Approved: ISOTRETINOIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approves a supplemental application for isotretinoin from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2018-04-23FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for AMNESTEEM (isotretinoin) filed by Mylan Pharmaceuticals Inc.
-
FDA approval · 2018-04-23FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc.
-
FDA label_change · 2018-04-16FDA Approved: TAZORAC — Supplemental Application (Almirall, LLC)
The FDA approved a supplemental application for TAZORAC (tazarotene) from Almirall, updating the product’s labeling.
-
CLINICAL_TRIALS trial_result · 2018-04-04Clinical Trial Update: Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring [NA]
A completed clinical trial comparing microneedling day-care procedure with tazarotene 0.1% gel for atrophic post-acne scarring. The snippet …
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Apelin12 in Acne Vulgaris
An update on the clinical trial of Apelin12 for Acne Vulgaris; the current trial status is unknown based on the provided snippet.
-
FDA approval · 2018-03-23FDA Approved: DIFFERIN — Supplemental Application (Galderma Laboratories, L.P.)
FDA approved a supplemental application for DIFFERIN (adapalene) from Galderma Laboratories, L.P.
-
CLINICAL_TRIALS research · 2018-03-19Clinical Trial Update: Studying the Skin Microbiome and the Potential of a Topical Probiotic Cream for Patients With Acne [NA]
This ClinicalTrials.gov entry describes an ongoing study, sponsored by University Hospital Antwerp, evaluating the skin microbiome and the p…